Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPM-01 in Becker Muscular Dystrophy
NCT04386304Phase 1Completed
- Sponsor
- Epirium Bio
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Catechin in Becker muscular dystrophy (BMD), sponsored by Epirium Bio. Primary endpoint: Number of participants with treatment-emergent adverse events up to 1 year. Started Jul 2020; status: completed.
02
Drugs
Catechin
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT04386304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386304.